Embed this press release by copying the code below:
PlasmaTech Biopharmaceuticals' Announces Initiation of Enrollment of MuGard Trial for Afinitor (Everolimus; Novartis) - Related Stomatitis at UCLA Breast Cancer Center
PlasmaTech Biopharmaceuticals' Announces Initiation of Enrollment of MuGard Trial for Afinitor (Everolimus; Novartis) - Related Stomatitis at UCLA Breast Cancer Center